Investor Overview Press Releases July 9, 2019 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% July 3, 2019 Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors June 26, 2019 Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints View all » Events Jun 26, 20195:00 PM EDT Aclaris Presents Top-Line Data from AA-201 Topical Phase 2 Trial Jun 20, 201911:30 AM EDT Aclaris Therapeutics, Inc. at 2019 JMP Securities Life Sciences Conference Jun 17, 20198:00 AM EDT Aclaris Presents 6-Month Results From Androgenetic Alopecia Study View all » Feature presentation Aclaris Therapeutics Company Overview
July 9, 2019 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1%
June 26, 2019 Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
